LIMN · XBRL financial data
Liminatus Pharma financial statements, every quarter
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (LIMN's year ends in late December)
| In thousands of dollars | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Research and development | — | — | — | — | 400 | 600 |
| General and administrative | 264 | 1,118 | 701 | 884* | 701 | 779 |
| Total operating expenses | 264 | 1,118 | 701 | 884* | 1,101 | 1,379 |
| Operating income (loss) | (0) | (1,118) | (701) | (884)* | (1,101) | (1,379) |
| Interest income | 52 | 24 | 0* | 0* | — | — |
| Interest expense | 116 | 62 | 19 | 19* | 19 | 19 |
| Net income (loss) | (0) | 113 | (1,823) | (8,169)* | (1,124) | (1,407) |
| Earnings per share, basic USD per share | (2.55) | 0.00 | (0.07) | — | (0.03) | (0.03) |
| Earnings per share, diluted USD per share | (2.55) | 0.00 | (0.07) | — | (0.03) | (0.03) |
| Weighted average shares, basic thousands of shares | 0 | 23,301 | 27,008 | — | 36,000 | 48,398 |
| Weighted average shares, diluted thousands of shares | 0 | 23,301 | 27,008 | — | 36,000 | 48,398 |
Balance sheet
CSVFiscal quarters (LIMN's year ends in late December)
| In thousands of dollars | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 1,338 | 725 | 338 | 1,908 | 3,017 |
| Prepaid and other current assets | — | 444 | 479 | 163 | 871 | 375 |
| Total current assets | — | 1,782 | 1,203 | 501 | 2,779 | 3,392 |
| Property and equipment, net | — | 0 | 13 | 12 | 12 | 11 |
| Total assets | — | 1,909 | 1,342 | 513 | 2,790 | 3,404 |
| Accrued liabilities | 1 | — | — | — | — | — |
| Total current liabilities | — | 10,516 | 2,865 | 10,298 | 2,889 | 3,040 |
| Total liabilities | 1 | 10,716 | 2,988 | 10,327 | 2,923 | 3,103 |
| Accumulated deficit | (1) | (28,879) | (30,703) | (38,872) | (39,995) | (41,403) |
| Total stockholders' equity | (1) | (8,807) | (1,646) | (9,815) | (133) | 301 |
| Total liabilities and equity | — | 1,909 | 1,342 | 513 | 2,790 | 3,404 |
| Common shares outstanding (cover page) thousands of shares | 26,015 | 27,065 | 27,065 | 44,878 | 44,878 | 67,160 |
Cash flows
CSVFiscal quarters (LIMN's year ends in late December)
| In thousands of dollars | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (0) | 113 | (1,823) | (8,169)* | (1,124) | (1,407) |
| Net cash from operating activities | 0 | (8,976)* | (601)* | (387)* | (2,015) | (970)* |
| Purchases of property and equipment | — | — | — | 0* | — | — |
| Net cash from investing activities | (575) | (200)* | (13)* | 0* | — | — |
| Net cash from financing activities | 713 | 10,320* | 0* | 0* | 3,585 | 2,079* |
| Net change in cash | 0 | 1,282* | (614)* | (387)* | 1,570 | 1,109* |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Liminatus Pharma | 3,017 | not reported | (970)* | 67.2M | 3.1 quarters | 10-QJun 30, 2026 |
| Precigen | 16,329 | 54,978 | (17,809)* | 358.0M | 2.1 quarters | 10-QJun 30, 2026 |
| SELLAS Life Sciences Group | 138,343 | not reported | (7,588)* | 201.9M | 18.2 quarters | 10-QJun 30, 2026 |
| Lifecore Biomedical | 17,241 | not reported | (2,189)* | 37.9M | 7.9 quarters | 10-QJun 30, 2026 |
| Sagimet Biosciences | 165,896 | not reported | (11,099)* | not reported | 21.6 quarters | 10-QJun 30, 2026 |
| Perspective Therapeutics | 48,488 | not reported | (20,650)* | 114.2M | 11.5 quarters | 10-QJun 30, 2026 |
| Rocket Pharmaceuticals | 224,507 | 0 | (39,613)* | 109.8M | 7.2 quarters | 10-QJun 30, 2026 |
| Natures Sunshine Products | 82,503 | 116,985 | 835* | 17.6M | — | 10-QJun 30, 2026 |
| Aldeyra Therapeutics | 45,090 | not reported | (4,589)* | 60.3M | 9.8 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.